Abstract
Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.
| Original language | English |
|---|---|
| Journal | American Journal of Ophthalmology |
| Volume | 155 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2013 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Topiramate use and the risk of glaucoma development : A population-based follow-up study. / Ho, Jau Der; Keller, Joseph J.; Tsai, Ching Yao; Liou, Shiow Wen; Chang, Chih Ju; Lin, Herng Ching.
In: American Journal of Ophthalmology, Vol. 155, No. 2, 02.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Topiramate use and the risk of glaucoma development
T2 - A population-based follow-up study
AU - Ho, Jau Der
AU - Keller, Joseph J.
AU - Tsai, Ching Yao
AU - Liou, Shiow Wen
AU - Chang, Chih Ju
AU - Lin, Herng Ching
PY - 2013/2
Y1 - 2013/2
N2 - Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.
AB - Purpose: To investigate the risk of glaucoma development after being prescribed topiramate. Design: A retrospective, population-based cohort study using an administrative database. Methods: The study group comprised 1956 patients who received their first prescription of topiramate between 2001 and 2007. The comparison cohort consisted of 15 648 randomly matched patients who never took topiramate. Each sampled patient was traced for a 1-year period from his or her index date to identify patients who subsequently received a diagnosis of glaucoma. Results: Glaucoma was diagnosed in 0.36%, 0.05%, and 0.66% of the study cohort during the first month, second to third month, and fourth to twelfth month following the index date, respectively. For the comparison cohort, glaucoma was diagnosed in 0.04%, 0.11%, and 0.46% of subjects during the first month, second to third month, and fourth to twelfth month following the index date, respectively. After adjusting for potential confounding factors, patients prescribed topiramate were found to have a 7.41-fold (95% confidence interval [CI] = 2.45-22.46) greater risk of subsequently being diagnosed with glaucoma than the comparison cohort during the first month after the index date. However, this association became statistically nonsignificant during the second-to-third-month and fourth-to-twelfth-month periods following the index date between the 2 cohorts (adjusted hazard ratio, 0.56, 95% CI = 0.07-4.29; and 1.35, 95% CI = 0.74-2.47, respectively). Conclusions: Topiramate use in Taiwan was associated with a significantly increased risk of being diagnosed with glaucoma within the first month after receiving a prescription for the drug.
UR - http://www.scopus.com/inward/record.url?scp=84872299046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872299046&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2012.07.016
DO - 10.1016/j.ajo.2012.07.016
M3 - Article
C2 - 23022160
AN - SCOPUS:84872299046
VL - 155
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 2
ER -